Quantum Genomics Logo

Quantum Genomics

Develops digital twin solutions to simulate drug effects and personalize treatments.

ALQGC | PA

Overview

Corporate Details

ISIN(s):
FR0010783837 (+4 more)
LEI:
969500TFCD8K9RPM9K97
Country:
France
Address:
6 RUE CAMBACERES, 75008 PARIS
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Quantum Genomics is a biopharmaceutical company that has historically specialized in the research and development of a new class of drugs for cardiovascular diseases, particularly resistant hypertension and heart failure. The company's core innovation was based on Brain Aminopeptidase A Inhibition (BAPAI), a novel mechanism targeting the brain to regulate blood pressure, with firibastat as its lead drug candidate. Following a strategic reorientation in 2024, Quantum Genomics acquired ExactCure, a company developing a digital twin solution. This technology aims to simulate drug effects in individual patients to optimize dosage, personalize treatments, and prevent adverse drug interactions, shifting the company's focus towards personalized medicine and digital health solutions.

Social Media

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Quantum Genomics and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-13 18:00
Post-Annual General Meeting Information
Report de l'Assemblée Générale Mixte du 30/06/2025
French 116.4 KB
2025-04-30 20:00
Earnings Release
Quantum Genomics publishes its 2024 annual financial statements and announces a…
English 206.5 KB
2025-04-30 20:00
Delisting Announcement
Quantum Genomics publie ses comptes annuels 2024 et annonce un changement de li…
French 254.0 KB
2025-04-08 08:00
Delisting Announcement
Quantum Genomics fait un point sur sa situation
French 688.8 KB
2025-04-08 08:00
Delisting Announcement
Quantum Genomics provides an update on its situation
English 626.0 KB
2024-10-29 18:00
Earnings Release
Quantum Genomics publie ses résultats du 1er semestre 2024 et annonce la nomina…
French 241.2 KB
2024-09-27 08:00
Legal Proceedings Report
Quantum Genomics sécurise un financement avec le fonds Akkadian Partners Fund e…
French 74.5 KB
2024-09-04 18:00
Legal Proceedings Report
Quantum Genomics reviewed its financial situation and announced that it has fil…
English 175.5 KB
2024-09-04 18:00
Legal Proceedings Report
Quantum Genomics fait un point sur sa situation financière et annonce qu'elle a…
French 150.0 KB
2024-07-03 13:00
Capital/Financing Update
BILAN SEMESTRIEL S1 DU CONTRAT DE LIQUIDITE CONTRACTE AVEC LA SOCIETE DE BOURSE…
French 275.3 KB
2024-03-13 18:00
Business and Financial Review
Quantum Genomics publie ses résultats de l'exercice 2023. Le rapprochement avec…
French 193.8 KB
2024-03-13 18:00
Earnings Release
Quantum Genomics publishes its results for the 2023 financial year. The merger …
English 166.3 KB
2024-01-10 16:35
Capital/Financing Update
Bilan au 29 décembre 2023 du contrat de liquidité contracté avec la Société de …
English 297.2 KB
2024-01-10 16:30
Capital/Financing Update
Bilan au 29 décembre 2023 du contrat de liquidité contracté avec la Société de …
English 297.2 KB
2023-12-14 18:05
Regulatory News Service
Quantum Genomics enters into exclusive negotiations with ExactCure
English 286.1 KB

Automate Your Workflow. Get a real-time feed of all Quantum Genomics filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Quantum Genomics via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN

Talk to a Data Expert

Have a question? We'll get back to you promptly.